US Enforcement 2019: Compounding, Opioids Top Priorities But Beware Of REMS Violations, Too
Executive Summary
Drug manufacturer reimbursement support services also are garnering a growing amount of enforcement attention, and misleading promotion - whether on- or off-label - remains on the radar of government investigators.
You may also be interested in...
Opioid Labeling Instructions On Naloxone Are Compromise In Co-Prescribing Debate
US FDA says opioid and opioid use disorder treatment labels should suggest providers discuss naloxone availability with patients and caregivers and consider co-prescribing to patients at high-risk of overdose, but it does not mandate co-prescribing, the most aggressive (and costly) option that had been considered.
Yell It From The Rooftops: Hep C Drug Safety Notice Another Example Of FDA's Limited Power Over Prescribers
After its bully pulpit, the US FDA's options to encourage physicians to follow labeling recommendations for hepatitis C drugs are limited.
Gottlieb Worries Vaccine Policy Could Spark Federalism Debate
Vaccination policies could result in arguments over states' rights instead of public health concerns, outgoing US FDA commissioner warns.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: